Navigation Links
Neither Management Nor Students Happy With New Fee Structure

The Shikshan Shulk Samiti, a committee appointed by the Supreme Court had on Thursday announced in Mumbai a 10% fee hike for the 29 private unaided medical// and dental colleges across the state.

VJ Kulkarni the committee spokesperson explained that the fee structure was fixed after taking into account the total expenditure incurred by the colleges. The managements are however not too pleased by the increase and have written to committee chairman Justice A C Agarwal in this respect.

The managements of private collages have expressed their unhappiness with the ‘dismal hike’, claiming that they wouldn’t be able to run their colleges’ according to the standards of the Medical Council of India and Dental Council of India.

Dr AM Vare, president of the Association of Private Unaided Medical and Dental Colleges (APUMDC), has said, “This interim fee structure cannot be justified. It is difficult for us to run a medical college with such a low fee structure.

Meanwhile scores of students aspiring to become doctors are greatly unhappy with the hike. The parents have expressed their feelings that the medical education is going out of reach for the middle class families.

It was expressed that students who want to be doctors are just being discouraged. One such a parent, Juliet Crasta, said her daughter might give up her dream of being a doctor and opt for a BSc degree instead.

A spokesman for the Parents' Association of Medical Students Rajesh Jain said, "It's not just the exorbitant fees, it's also the poor quality of infrastructure," while explaining that the association has been fighting several legal battles over this issue from the past few years.
'"/>




Page: 1

Related medicine news :

1. New Modality in Migraine Management
2. Self-Management Program Beneficial for Back Pain
3. Self-Management Program Beneficial for Back Pain
4. Disease Management Programs – Effective for Heart Patient
5. Effective Management Of Heart Patients
6. Gastrin, Much More Than The Weight Management Hormone
7. Medical Management Now Available For Miscarriage
8. Early Awareness About Weight Management Needed To Tackle Lifelong Obesity
9. Exercise For Effective Pain Management In Old People
10. Novel Technique For Management Of Inverted Papilloma Of Frontal Sinus
11. Guidelines For Better Management Of Obsessive-Compulsive Disorder
Post Your Comments:
Breaking Medicine Technology:Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 2Sangart, Inc. Initiates Phase IIa Study of Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients With Hemorrhagic Shock 3FDA Launches Orphan Drug Workshop at KGI 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 1Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 2Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 3Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 4Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 5Angiotech Pharmaceuticals announces FDA 510 28k 29 clearance of the Option 28TM 29 Inferior Vena Cava Filter 12515 6Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 1Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 2Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy Five Percent Accrual 4559 3Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 1Diamyd 28R 29 Phase III Study Approved for Younger Patients in the US 12511 2